Log In Sign up
The largest database of trusted experimental protocols

Cd235a pe cy7

Manufactured by BioLegend
Visit Supplier

CD235a PE-Cy7 is a fluorescently-labeled antibody that specifically binds to the CD235a (Glycophorin A) cell surface marker. It can be used for the identification and analysis of erythroid cells by flow cytometry.

Automatically generated - may contain errors

Lab products found in correlation

Cd56 pe, by BioLegend (1 mentions) Cd3 percp cy5.5 hit3a, by BioLegend (1 mentions) Cd8 apc hit8a, by BioLegend (1 mentions) Cd14 bv510 m5e2, by BioLegend (1 mentions) Cd45 bv786, by BD (1 mentions) Cd11c bv605, by BioLegend (1 mentions) Human fcr blocking reagent, by Miltenyi Biotec (1 mentions) Cd29 pe, by Thermo Fisher Scientific (1 mentions) Cd45 pe cy7, by BioLegend (1 mentions) Cd90 fitc, by BioLegend (1 mentions) Cd31 pe cy7, by BioLegend (1 mentions) Cd105 pe, by Thermo Fisher Scientific (1 mentions) Apc pdpn, by BioLegend (1 mentions) Cd44 apc, by Thermo Fisher Scientific (1 mentions) Facsaria 2, by BD (1 mentions) Clone hi30, by BioLegend (1 mentions) Streptavidin af488, by Thermo Fisher Scientific (1 mentions) Cd45 bv510, by BioLegend (1 mentions) Cd31 apc cy7, by BioLegend (1 mentions) Anti biotin magnetic beads, by Miltenyi Biotec (1 mentions)

4 protocols using cd235a pe cy7

1

Multilineage Differentiation Potential Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lymphoid, myeloid, and erythroid differentiation potential was determined using FACS analysis at 1 week post DOX induction. In all, 100% growth was obtained from all wells seeded with 300 targeted or mock-treated cells. Media were removed from all positive wells and cells were washed in 1× PBS. Cells were re-suspended in 50 μl MACS buffer (1× PBS, 2% FBS, 2 mM EDTA), blocked for nonspecific binding (5% vol/vol human FcR blocking reagent, Miltenyi, cat no. 130-059-901), stained for live dead discrimination using Live/Dead blue dead cell staining kit for UV (ThermoFisher Scientific, cat no. L23105) and stained (30 min, 4 °C dark) using CD3 PerCP/Cy5.5 (HiT3A, BioLegend), CD4 BV650 (OKT4, BioLegend), CD8 APC (HiT8a, BioLegend), CD11c BV605 (3.9, BioLegend), CD14 BV510 (M5E2, BioLegend), CD19 FITC (HIB19, BioLegend), CD33 AF-300 (WM53, BD Pharmingen), CD45 BV786 (BD Pharmingen), CD56 PE (MEM-188 BioLegend), CD235a PE-Cy7 (HI264, BioLegend), and CD271 (tNGFR) CF-594 (C40-1457, BD Horizon).
Pavel-Dinu M., Wiebking V., Dejene B.T., Srifa W., Mantri S., Nicolas C.E., Lee C., Bao G., Kildebeck E.J., Punjya N., Sindhu C., Inlay M.A., Saxena N., DeRavin S.S., Malech H., Roncarolo M.G., Weinberg K.I, & Porteus M.H. (2019). Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nature Communications, 10, 1634.
+ Open protocol
+ Expand
2

Multiparametric Flow Cytometry of ACSCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The following antibodies were used: CD45-PE-Cy7 (Biolegend, 304,016, 5 μL/test), CD31-PE-Cy7 (Biolegend, 303,118, 5 μL/test), CD235A-PE-Cy7 (Biolegend, 349,112, 5 μL/test), CD29-PE (eBioscience, 12-0299-41, 5 μL/test), CD44-APC (Invitrogen, 17–0441-81, 5 μL/test), CD90-FITC (Biolegend, 328,108, 5 μL/test), CD105-PE (Invitrogen, 1,930,337, 5 μL/test) and PDPN-APC (Biolegend, 337,022, 5 μL /test). ACSCs were stained in 100 μL PBS for 30 min at 4 °C, washed once and resuspended in PBS. Unstained cells were used as control. Flow cytometry was performed on BD FACS Aria II. The analyses was performed using Flowjo 8.0.
Li Z.L., Li X.T., Hao R.C., Wang F.Y., Wang Y.X., Zhao Z.D., Li P.L., Yin B.F., Mao N., Ding L, & Zhu H. (2023). Human osteoarthritic articular cartilage stem cells suppress osteoclasts and improve subchondral bone remodeling in experimental knee osteoarthritis partially by releasing TNFAIP3. Stem Cell Research & Therapy, 14, 253.
+ Open protocol
+ Expand
3

Immunophenotyping of Hematopoietic Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
Frozen BM aspirates were thawed on ice and stained with biotinylated antibodies against CD45 (1:50, clone HI30; BioLegend) and CD235a (1:50, clone HIR2, BioLegend) followed by depletion using magnetic anti-biotin beads (20 μL per 107 cells; Miltenyi Biotec) in PBS supplemented with 2% FCS and iMag (BD Biosciences). After depletion, the remaining cells were stained in PBS containing 0.5% FCS at 4°C with the following antibodies: Streptavidin-AF488 (1:100, Invitrogen), CD45-BV510(1:50, clone HI30; BioLegend), CD235a-PE-Cy7(1:50, clone HI264; BioLegend), CD71-AF700 (1:20, clone MEM-75; Exbio), CD271-PE (1:50, clone ME20.4; BioLegend), CD31-APC-Cy7 (1:20, clone WM59; BioLegend), and CD44-APC (1:50, clone IM7, Sony). 7AAD (1:100; Beckman Coulter) was used for dead cell exclusion. Samples were measured using FACSymphony A5 Cell Analyzer and analyzed with a FlowJo_v10.6.1 program.
Chen L., Pronk E., van Dijk C., Bian Y., Feyen J., van Tienhoven T., Yildirim M., Pisterzi P., de Jong M.M., Bastidas A., Hoogenboezem R.M., Wevers C., Bindels E.M., Löwenberg B., Cupedo T., Sanders M.A, & Raaijmakers M.H. (2023). A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML. Blood Cancer Discovery, 4(5), 394-417.
+ Open protocol
+ Expand
4

Multilineage Differentiation Profiling

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Antibodies to the transferrin receptor, an erythroid precursor marker, CD71 APC-Cy7 (Biolegend Cat # 33410) and the glycophorin A erythrocyte marker CD235a PE-Cy7 (Biolegend Cat # 349112) were used for surface staining to evaluate erythroid lineage differentiation. Appropriate isotype controls from Bio Legend were used for gating. Myeloid lineage detection was evaluated using surface markers CD24 APC (Biolegend Cat # 311118) and CD33 PE-Cy5 (Biolegend Cat # 303406). Following surface marker staining, cells were fixed with fixation buffer (Bio Legend Cat # 420801), permeabilized with Foxp3/Transcription Factor Staining Buffer Set (Invitrogen eBioscience Cat # 00552300) and stained for ARID3a with goat antihuman ARID3a peptide-specific antibody, as we described previously (31 (link)). Donkey anti-goat IgG PE (Invitrogen Cat# Pl31860) was used as the secondary antibody. Data were collected on a Stratedigm S1200Ex and data post processing and analysis was performed using FlowJo (Tree Star) software version 10.
Garton J., Shankar M., Chapman B., Rose K., Gaffney P.M, & Webb C.F. (2021). Deficiencies in the DNA Binding Protein ARID3a Alter Chromatin Structures Important for Early Human Erythropoiesis. ImmunoHorizons, 5(10), 802-817.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!